Tell Us Your Story: Allison Galloway

Somehow I made it through 37 years of life without ever meeting a blind person.

Then my 3-year-old son was diagnosed with a rare genetic disease called Leber congenital amaurosis (LCA) that will cause him to go blind in his teens or twenties. My world was set into a whirlwind of grief, confusion and anger.

How was it possible that two completely healthy parents who did everything the doctors told us to do before and during pregnancy, could have a child with such a traumatizing diagnosis?

As the weeks went on my grief turned to anger, my anger to guilt, my guilt to a desire to solve the problem to which there was no solution.

This disease caused my son’s body to lack the ability to create a simple enzyme called retinal dehydrogenase, which assists in the cleaning and health of the rods and cones in his eyes. It is an autosomal recessive gene defect that appears when each parent has a mutation on the same gene in the same place. There is a 25 percent chance that each child they create will have this disease. The odds were against us, I suppose.

A year and a half later, we learned the odds were even worse than we thought. Our son was 5 and our daughter was 3. One day at dinner I noticed my daughter’s eye started to bounce from side to side. I immediately knew what it meant. A nystagmus means that the eye is weak and sick. I didn’t need the gene results to know that not only did my son have LCA, but my beautiful little girl did too. A 6 percent chance …

LCA diagnosis is truly life changing

There are social repercussions to a diagnosis like this. I lost friends because they couldn’t cope with the thought of a child losing his sight. My son has had kids tell him he can’t do certain things because he is the “blind kid” (and he is only in kindergarten). People told me that what I was feeling about my kids’ diagnosis —that sense of loss or death of the life that you thought your child would have —was the wrong way to feel.

What fueled my determination to speak out for all those parents dealing with a similar heart-sinking diagnosis occurred at our eye doctor’s of all places. I walked into the office determined to figure out what was wrong with my son’s eyes. After an hour and a half, the doctor handed me my child’s diagnosis on a piece of paper. She told me to schedule a procedure under anesthesia for my son at Children’s Hospital with no explanation of why or what we were looking for and then told me to follow up in a year “if I wanted to.”

I Googled what was written on that paper. The first word I saw was “blind” and the second phrase that stood out was “no cure.” That was all I had. I am a nurse practitioner but I had very little knowledge of the eye. I knew then and there that I quickly had to learn all I could. The problem is that so many families get the same kind of “rare disease news” and have no idea what to do. They trust their doctors to be the knowledgeable ones. If a doctor says there is no cure, well then there is no cure, right? Nothing left to do but learn how to accept it, scared and alone.

You are not alone

I want to stand up for all those parents out there who don’t know where to go once they hear something hard about their child. I have met many families who have had similar diagnoses as my children and the doctors tell them that there is no cure yet, so there is no need to do anything but deal. This infuriates me. The lack of assistance given to parents is astounding. If I had not had the financial means, the education, and the network, I would have taken the advice of my first doctor and just followed up ” if I wanted to.”

As time has gone on I have met so many amazing parents, families, teachers, and researchers who are determined to cure many of these rare diseases. Social media has opened so many doors. I was lucky to find a group of 18 families whose children all have the same gene defect as mine, RDH12. Together we created a network of motivated parents who have formed a 501(c)(3) named RDH12.org to raise money. We work with scientists around the world to fund research. We support each other even if we live in the U.S., Italy, Australia or Saudi Arabia. We try to advocate the importance of all children diagnosed with a rare disease to get genetic testing. Without it we would have never known what our children had, let alone how to cure it.

Use the resources

There are amazing things out there like the website, Myretinatracker.org, which was created to generate a database of everyone with inherited retinal disease so scientists can easily access a population to use for clinical trials. Everyone should be on it if they have a genetic disorder.

Genetic testing is free in many instances and all it requires is a simple blood test. Spark Therapeutics has just started an ID YOUR IRD gene testing initiative for free to patients that aims to help inform as many people as possible of their specific gene test. Knowing the gene is a critical step towards getting treatment if it is available or toward helping advance the research that will lead to cures. It is for this reason that I am writing to you. There is so much that we can do if we have the knowledge to do so and we spread the word.

This rare disease is what comes between my children and the world. It limits them. Rare has flipped our world upside down and forever changed me. It keeps me searching for answers and fighting for all those families out there. We know our love is what keeps us going on the days that feel impossible. Love is what will keep us moving on the days when the news at appointments is less than positive. We never give up on our children, and we will never stop fighting for their well-being. All we want is for our children to not have to fight so hard to simply be.

Allison Galloway lives in Westminster, Colorado, with her husband Michael and their two children, 6-year-old Logan and 4-year-old Zoe.

Successful Strategies for Patient Organizations

Your voice counts! Lawmakers on the state level need to hear from people living with Leber congenital amaurosis (LCA) and other rare diseases to help secure funding for research, patients’ needs, costs associated with living with a rare disease and accessibility on all fronts.

Your voices and those of organizations representing the rare disease community need to be heard by your state senators and representatives now to prevent elimination or reduction in funding, especially in these times of tight budgets.

This advice came during a conference workshop – Successful Strategies for Patient Organizations – at the recent 2017 Rare Disease & Orphan Products Breakthrough Summit presented by the National Organization for Rare Disorders (NORD).

Rare diseases number more than 7,000. You can make a difference because of the power in numbers. Start making contacts now as we approach Rare Disease Day on Feb. 28, 2018. Plan to combine efforts with other rare disease organizations in your state and rally for cures, regardless of the disease/gene that you represent.

Rare disease community members represent 10 percent of legislators’ constituents. Know that number before you meet. For instance, if 20,000 people live in your district, 2,000 live with rare diseases.

The legislators in any state’s capital, work for you. Don’t be intimidated; realize the impact you can have by reaching out and/or meeting with your representative or senator. Research them in advance online, find out on which committees they serve, when and where they are in session, and contact their offices regularly.

For instance, in Connecticut, the Human Services Committee has jurisdiction over all matters relating to the Department of Social Services and would include services for the rare disease community.

Meeting with legislators or their staff does not have to happen at their offices. Build a relationship by inviting them to key events and meeting them at theirs. Always say hello so you stand out from the crowd. Keep calling and keep emailing.

Tell them your personal rare disease stories. Talking from the heart has impact. Even if they oppose your proposals for legislation, they’ve heard your story and you’ve offered them a worthwhile perspective that in the end may help change their minds.

Brings notes to keep on-point. Avoid making your pitch sound too complex and don’t share irrelevant information. Leave behind business cards and notepads or pens imprinted with your organization’s logo. Follow up the meeting with a thank-you card and a phone call.

Also, your best friends in the world of lawmakers are their staff members. Staffers keep track of legislators’ calendars and decide when meetings take place. If you do secure a meeting with staff and not the legislator, don’t be insulted as this often is the first step in meeting with a lawmaker in person. Staffers will relay your key points.

Remember, legislators want to do a good job representing the people in their district. They do that by receiving pertinent information from you and your organizations so they can make a difference by developing, sponsoring and enacting legislation beneficial to our rare disease community.

2017 Rare Disease & Orphan Products Breakthrough Summit

A two-day conference in Washington, D.C., earlier this month offered the opportunity for organizations such as Hope in Focus (formally Sofia Sees Hope) to discover the latest in the rare disease community, meet the nation’s top rare-disease professionals, and gather resources and ideas to help with the Leber congenital amaurosis (LCA) community.

More than 670 people attended the first day of the 2017 Rare Disease & Orphan Products Breakthrough Summit on Monday, Oct. 16.

The summit, presented by the National Organization for Rare Diseases (NORD) , included a range of topics, from the challenges of healthcare costs, to the ethical guidelines for patient organizations and themes of collaboration, urgency and transparency.

The summit’s second day featured presentations by the Food & Drug Administration’s leading Division Directors and discussions of improving the lives of patients with rare diseases.

Peter L. Saltonstall, President and CEO of NORD

The conference kicked off with a welcome by Peter L. Saltonstall, President and CEO of NORD, and Marshall L. Summar, M.D., Director of Children’s National Rare Disease Institute, Chief of Genetics and Metabolism at Children’s National Medical Center , and Chairman of NORD’s Board of Directors.

Key presentations included ensuring patient access, sustaining orphan drug development and availability, and reviewing achievements in rare disease drug, biologic and device development.

Mike Porath, founder and CEO of The Mighty and a parent of a child with a rare disease, gave a motivating, multi-faceted presentation in his keynote community address. His advice to families living with a rare disease included asking for help, embracing the moments and dreaming big to open doors for people with rare diseases.

Scott Gottlieb, M.D., Commissioner of the FDA, delivered the administration’s keynote address, talking about the group’s rare disease priorities, the rapid changes in rare disease product development and the basis of the Orphan Drug Act.

Presenting at FDA Hearing Thursday on RPE65 Genetic Therapy Drug

Hope in Focus (formally Sofia Sees Hope) Co-Founder Laura Manfre will help provide the LCA community’s perspective to a Food & Drug Administration panel Thursday about a proposed genetic therapy for Leber congenital amaurosis (LCA) caused by an RPE65 gene mutation.

“This is such an important event because it allows the patient population — the parents, and children and families — directly impacted by this very important decision-making process to be heard,” Manfre said. “The FDA has a critical job to do in weighing all of the potential risks and benefits with any drug approval, and they recognize that the voice and the experiences of those who are affected needs to be a part of that process.

“Part of Sofia Sees Hope’s mission is to help serve as a connection among families living with LCA,” Manfre continued. “We see this opportunity to offer testimony as another way to fulfill that mission.”

As a presenter at the FDA’s public advisory meeting of the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC), Manfre will be representing patients and families living with LCA and other rare inherited retinal diseases. The meeting begins at 8:30 Thursday morning and runs to 5 p.m. at the FDA White Oak Campus in Silver Spring, MD.

The CTGTAC is meeting to make recommendations on the safety and effectiveness of biologics license application for voretigene neparvovec, submitted by Spark Therapeutics, Inc. The proposed gene therapy is to treat patients with vision loss due to confirmed biallelic RPE65 mutation-associated dystrophy.

RPE65 mutation-associated retinal dystrophy is an orphan disease, with an estimated 1,000-3,000 patients affected in the United States, according to A Shared Vision.

Manfre said research and bringing therapies to market provides hope to all LCA and IRD families.

“Though families may struggle with the day-to-day challenges, they can have hope that there just might be a light at the end of the tunnel,” she said.

“To help foster this effort,” she said, “Patients and families need to seek diagnoses, participate in patient registries, and continue to generate awareness and make our voices heard. Our disease is rare, which makes it more important than ever that we are working together to be advocate for our community and to move treatment and cures for blindness forward.”

For the meeting, Spark submitted to the FDA a 149-page briefing detailing the history, background, studies and research that went into developing voretigene neparvovec, which has the proposed trade name LUXTURNA.

The FDA’s 42-page briefing details its analysis of the proposed treatment and offers discussion questions for the advisory committee that include at what age should patients receive treatment and what are the treatment’s potential risks and benefits.

Here are some links for more information about the meeting:

Webcast of the meeting: https://collaboration.fda.gov/ctgtac101217.

Alan’s Story: Gaining Independence with Aira Technology

Trust me when I tell you to grab a tissue. Or roll down your sleeves and get ready to wipe. Me? My eyes are welling up even as I type. Recently, I witnessed a miracle.

I’ll give you a little background while you look for a Kleenex. Twenty years ago, at the age of 8 weeks, my nephew Alan was diagnosed with Leber congenital amaurosis (LCA), a rare disease that limits retinal development. Holding her infant son, my sister Betsy and her husband David listened in disbelief as the retinal specialist explained that Alan would be visually impaired at best, and fully blind at worst. The doctor informed them there was no cure, no treatment, and no adaptive device to correct their son’s condition.

Like his sighted peers, Alan attended public school. His mobility instructor taught him to navigate familiar

Alan Brint, who is blind, is trailed by his mother Betsy and his dog Mo, tries out his new Aira glasses. Aira’s platform works on a wearable device similar to Google glass, that can be paired with a smart phone. The tiny camera mounted on the device [cool sunglasses] provides instant feedback to a trained Aira agent who can safely guide [a wearer] in any activity. Alan was navigating his way to his local train station using an unfamiliar route as a test of the technology.parts of his world with his white cane. By sixth grade, he could walk to school by himself. Now a junior at Beloit College, he’s doing just fine. That’s not the miracle.

Not to dismiss Alan’s role in his accomplishments, but his successes have been in some part reliant on a team of people. Still, there are limits to his independence. Spoiler alert: here comes the miracle.

Last week, Betsy called me. “Get outside now. Alan is walking to the train station. By himself. He’s near the library. Run.”

I ran. Turning the corner, I saw my nephew, cane in hand, walking a route new to him. Betsy trailed silently, about 10 feet behind.

“Hey Aunt Sally. Is that you?” Cue the tears. Remember, Alan is blind. He has never seen me coming his way. For 20 years, we’ve all come up to him and touched him, or spoken to him, or hugged him, letting him know we were there. For the first time, he “saw” me coming.

Alan was wearing an adaptive technology, and it was changing his life in front of my tearing eyes.

The technology is called Aira (eye-rah). According to their website, “Aira’s platform works on a wearable device similar to Google glass, that can be paired with a smart phone. The tiny camera mounted on the device [cool sunglasses] provides instant feedback to a trained Aira agent who can safely guide [a wearer] in any activity.”

Alan’s Aira glasses had arrived the day before. The device is free, and the glasses are free. Like a cell phone contract, users pay a monthly service fee based on the minutes they use. When it’s on, an agent sees a split screen. On one side is a GPS view, to map out the exact location of the route guidance. On the other screen, the agent sees the lens view from the user’s camera. Simple, yet genius.

I fell in step with Betsy, following Alan’s lead for the first time. He made it easily to the train station, then home via a different route. Since then, he’s walked to a local bagel shop and “read” menus. I asked Alan, “What do you like best about this?”

“I like walking somewhere that I’ve never walked to before, by myself, without learning the route. I like reading menus. I like finding people. I found you!”

I turned to my sister. “Well? What are you thinking?”

“It’s totally selfish. I want to be his eyes,” she said.

“Don’t you think you’ve been his eyes?”

“Yeah, I guess. And now I’m turning it over to somebody else.”

There wasn’t a dry eye between us.

Hope in Focus (formally Sofia Sees Hope) is dedicated to ending the isolation that LCA families can feel after their diagnosis by sharing their stories. Read more here. Would you like to share your story? Email info@hopeinfocus.org

Attention LCA Families: Sign up to receive the LCA Family Newsletter!

Hope in Focus (formally Sofia Sees Hope), a nonprofit focused on families living with Leber congenital amaurosis (LCA), will launch a quarterly newsletter in the fall of 2017.

Sofia Sees Hope funds research for diagnosis, treatments and cures for rare retinal disease and provides advocacy and information for the LCA community.

The newsletter will be specifically for LCA patient families to help them connect with each other and with the resources and organizations that can help them. The newsletter will have both a print and a digital version.

“There used to a be a newsletter for LCA families and it was a wonderful resource and a great way to stay informed,” said Sofia Sees Hope co-founder Laura Manfre. “When I attend conferences and hear from families the number one thing other patient families say to me, is they miss the newsletter. I’m happy that Sofia Sees Hope is now in a position to do this.”

September 2017 launch

The newsletter will include LCA research news; contact information for research and trials, family stories, fundraisers, an event calendar, and a section dedicated to education on the patient and family role in advancing research.

Sofia Sees Hope has assembled a team of former journalists to spearhead the project, ensuring that the information it contains will be factual and trustworthy for patient families.

To sign up for the newsletter — and other information from Sofia Sees Hope — please visit this page: https://hopeinfocus.org/resources/newsletter/

You can also send article suggestions to Sofia Sees Hope by visiting https://hopeinfocus.org/contact/.

Sign up for our Newsletter

Love Golf? Hate Golf? Both Can Help Cure IRDs and LCA!

Birdies for Charity is a great program that we joined this year to help us raise awareness about Leber congenital amaurosis (LCA) and to help raise funds to cure LCA and other rare inherited retinal disease (IRD). For golfers, it’s a chance to be part of the Travelers Tournament, a decades-long tradition that brings the PGA tour’s top players to Connecticut. For non-golfers, it’s an easy, fun way to help Hope in Focus (formally Sofia Sees Hope) by m aking a pledge as low as two cents per birdie.

It’s very simple and works like a walk-a-thon. People pledge some amount per birdie, just like they might pledge some amount per mile walked in a disease walk-a-thon. In this case, they usually pledge anywhere from two cents to one dollar per birdie, because professional golfers are likely to make about 1800 birdies during the tournament.

This part is for the non-golfers! A birdie means they hit “one under par” for a given golf hole. Par is the number of strokes (times you hit a golf ball) a person is likely to need to get the ball in the hole. A professional is expected to do much, much better than the average golfer, so they would normally be under par most of the time, requiring fewer strokes than normal people would. So they make a lot of birdies!

For the real golfers and fans, we have a limited number of day passes available for people who pledge. First come, first served, so click here to go to our dedicated Birdies for Charity page now!

To Test or Not To Test: 5 Reasons We Think You Can And Should Get a Genetic Diagnosis For Your IRD

Hey LCA or IRD family, does any of this sound familiar?

You or your child has received a clinical diagnosis of LCA (leber congenital amaurosis), RP (retinitis pigmentosa), cone-rod dystrophy, or another crazily-named inherited retinal disease AND…

Your doctor wants to help, but isn’t sure where to direct you or what to do next.
Your doctor doesn’t even think you should bother. (There aren’t any cures or treatments available so why waste your time and energy?)
You’ve been genetically tested at least once (and maybe five times before). No one gets back to you and if they do, the results are negative.
Your insurance company doesn’t want to cover the cost.
OMG, you’re frustrated! No one seems to be able to give you clear direction and you’re not getting any answers.

On one hand, we wish we could say this experience is rare and unique! But the truth is that you’re in good company. There is still so much confusion around getting to a genetic diagnosis for your inherited retinal disease. The good news is, we are not confused on one item: YOU NEED TO GET TESTED! And here are five reasons why.

Misdiagnosis is still more common than we wish. Until you have a genetic diagnosis, you just can’t be sure you really have LCA, or RP, or another IRD.
It’s not just about blindness. This is the somewhat scary part that you might not be aware of, but several of the genetic defects that come with these rare IRDs, also impact other organs. For example, some LCA genes are reno-retinal genes, meaning that they may also impact kidney function. We’re not sharing this information to scare you into getting tested, but to highlight just how important it is to make sure you have a clear, genetic diagnosis so you can be prepared and provide the best care possible for any other possible conditions.

Treatments and cures are coming! That tired story of don’t bother because there’s nothing you can do is bogus. There is already a proven treatment for one form of LCA (RPE65) and there will be others. If you don’t have a diagnosis, you can’t participate in clinical trials or take advantage of treatments as they become available. That is a real bummer.

We know where you can get tested. We are so close to cures and treatments today that there are FREE programs like Spark Therapeutics’ ID Your IRD and programs through the Foundation FIghting blindness that you may be able to take advantage of. Check out our website resources for information, or contact us and let us help!
Knowledge is power. ‘Nuff said.